Ascendis Pharma
ASND
ASND
167 hedge funds and large institutions have $5.87B invested in Ascendis Pharma in 2022 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 58 increasing their positions, 60 reducing their positions, and 31 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more ownership
Funds ownership: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less funds holding
Funds holding: →
6% less funds holding in top 10
Funds holding in top 10: 16 → 15 (-1)
19% less capital invested
Capital invested by funds: $7.27B → $5.87B (-$1.4B)
26% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 31
Holders
167
Holding in Top 10
15
Calls
$28.2M
Puts
$14.3M
Top Buyers
| 1 | +$145M | |
| 2 | +$98.6M | |
| 3 | +$41.4M | |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$28.9M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$27.4M |
Top Sellers
| 1 | -$104M | |
| 2 | -$68.8M | |
| 3 | -$49M | |
| 4 |
Invesco
Atlanta,
Georgia
|
-$39.5M |
| 5 |
VC
Vivo Capital
Palo Alto,
California
|
-$27.6M |